推进血液病中的治疗性补体抑制:PNH及更多疾病
补体是先天免疫系统,遗传变异和自身抗体导致补体过度激活参与多种人类疾病。血液病阵发性睡眠性血红蛋白尿症(PNH)仍是补体激活和抑制的原型模型。依库珠单抗是首个补体抑制剂,2007年获批用于PNH。针对未满足需求,长效C5抑制剂ravulizumab和C3抑制剂pegcetacoplan也已获批用于PNH。因子B和因子D抑制剂等新药正在研究中,结果非常有前景。在多种获批靶向补体治疗的时代,选择合适药物必须基于个体化方法。除PNH外,补体抑制在冷凝集素病中也显示出疗效和安全性,主要是经典补体途径的C1s抑制剂sutimlimab以及pegcetacoplan。此外,依库珠单抗和ravulizumab的C5抑制以及narsoplimab的凝集素途径抑制正在移植相关血栓性微血管病中研究。随着下一代补体治疗的革命,其他血液病实体,如迟发性溶血性输血反应或免疫性血小板减少症,也可能受益于补体抑制剂。因此,本综述旨在描述血液病中靶向补体的最新知识,重点关注:(1)临床医生的补体生物学,(2)原型补体介导的血液病中的补体激活和治疗性抑制,(3)正在研究补体抑制的血液病实体,(4)血液科医生可能感兴趣的其他补体相关疾病。
要点
- 依库珠单抗2007年获批用于PNH,ravulizumab和pegcetacoplan也已获批。
- 因子B和因子D抑制剂等新药在PNH中研究结果非常有前景。
- 补体抑制在冷凝集素病中显示疗效和安全性。
核心结论
- 补体抑制在PNH中已有多种获批药物,选择需个体化。
- 补体抑制在冷凝集素病中显示疗效和安全性。
- 其他血液病如迟发性溶血性输血反应或免疫性血小板减少症可能受益。
研究设计与样本
- 综述,描述血液病中靶向补体的最新知识。
主要发现
- 依库珠单抗2007年获批用于PNH。
- ravulizumab和pegcetacoplan已获批用于PNH。
- 因子B和因子D抑制剂在研究中,结果非常有前景。
- sutimlimab和pegcetacoplan在冷凝集素病中显示疗效和安全性。
- 依库珠单抗、ravulizumab和narsoplimab正在移植相关血栓性微血管病中研究。
临床怎么用
- PNH治疗选择应基于个体化方法。
- 冷凝集素病可考虑补体抑制治疗。
- 移植相关血栓性微血管病可研究性使用补体抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complement is an elaborate system of innate immunity. Genetic variants and autoantibodies leading to excessive complement activation are implicated in a variety of human diseases. Among them, the hematologic disease paroxysmal nocturnal hemoglobinuria (PNH) remains the prototypic model of complement activation and inhibition. Eculizumab, the first-in-class complement inhibitor, was approved for PNH in 2007. Addressing some of the unmet needs, a long-acting C5 inhibitor, ravulizumab, and a C3 inhibitor, pegcetacoplan, have also now been approved for PNH. Novel agents, such as factor B and factor D inhibitors, are under study, with very promising results. In this era of several approved targeted complement therapeutics, selection of the proper drug must be based on a personalized approach. Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease, primarily with the C1s inhibitor of the classical complement pathway sutimlimab, as well as with pegcetacoplan. Furthermore, C5 inhibition with eculizumab and ravulizumab, as well as inhibition of the lectin pathway with narsoplimab, is being investigated in transplantation-associated thrombotic microangiopathy. With this revolution of next-generation complement therapeutics, additional hematologic entities, such as delayed hemolytic transfusion reaction or immune thrombocytopenia, might also benefit from complement inhibitors. Therefore, this review aims to describe state-of-the-art knowledge of targeting complement in hematologic diseases, focusing on (1) complement biology for the clinician, (2) complement activation and therapeutic inhibition in prototypic complement-mediated hematologic diseases, (3) hematologic entities under investigation for complement inhibition, and (4) other complement-related disorders of potential interest to hematologists.
引用
- Gavriilaki E, de Latour RP, Risitano AM, et al. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood. 2022. PMID: 34482398. doi:10.1182/blood.2021012860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。